Evidence map›Paper›PMID 42318082›Full record

ArticleOncology letters2026

Cepharanthine suppresses lung adenocarcinoma through targeting glutathione peroxidase 4.

Ruoxue Cao, Sun Kang, Kun Wang, Yan Wang, Minghui Li, Qian Liu, Ying Zhang, Mei Fu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ruoxue CaoDepartment of Laboratory Medicine, The Second People's Hospital of Lianyungang, Lianyungang, Jiangsu 222006, P.R. China.
Sun KangDepartment of Hospital Infection Management, The Second People's Hospital of Lianyungang, Lianyungang, Jiangsu 222006, P.R. China.
Kun WangDepartment of Laboratory Medicine, The Second People's Hospital of Lianyungang, Lianyungang, Jiangsu 222006, P.R. China.
Yan WangDepartment of Laboratory Medicine, Lianyungang Clinical College Xuzhou Medical University and The Second People's Hospital of Lianyungang, Lianyungang, Jiangsu 222006, P.R. China.
Minghui LiDepartment of Laboratory Medicine, The Second People's Hospital of Lianyungang, Lianyungang, Jiangsu 222006, P.R. China.
Qian LiuDepartment of Laboratory Medicine, The Second People's Hospital of Lianyungang, Lianyungang, Jiangsu 222006, P.R. China.
Ying ZhangDepartment of Laboratory Medicine, The Second People's Hospital of Lianyungang, Lianyungang, Jiangsu 222006, P.R. China.
Mei FuDepartment of Laboratory Medicine, The Second People's Hospital of Lianyungang, Lianyungang, Jiangsu 222006, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer poses a marked threat to global health, with lung adenocarcinoma (LUAD) being a predominant subtype. Despite their availability, treatment options often fall short of expectations. In this context, Traditional Chinese Medicine, known for its multifaceted therapeutic effects and favorable safety profile, has emerged as a promising alternative. In particular, cepharanthine (CEP), a bisbenzylisoquinoline alkaloid derived from

Indexed as

cepharanthineGene Expression Omnibusglutathione peroxidase 4lung adenocarcinoma

Identifiers

PMID42318082
PMCPMC13273163

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.